Founded in 2008, NGM is a privately-held drug discovery company in South San Francisco, California committed to the identification and development of transformational biologics for diabetes, obesity and other cardio-metabolic diseases. NGM has established collaborations with Daiichi Sankyo, Janssen Pharmaceuticals, MedImmune and JDRF.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/18/13 | $50,000,000 | Series C |
Prospect Venture Partners Rho Ventures The Column Group Tichenor Ventures Topspin Fund | undisclosed |
